#myelodysplasia — Wednesday, September 16, 2026 (1 items)
| 0 | ℹ |
Canakinumab or emavusertib for anemia in lower-risk MDS: results of the CANFIRE and LUCAS phase 2, open-label, multicenter trials.
(nature.com)
|
Communications Medicine 2026-09-16 | #anemia #myelodysplasia #immunotherapy #inflammation #hematopoiesis |